TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06622070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPY002-072
Description: Experimental

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05079516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theta burst transcranial magnetic stimulation
Description: Real or sham continuous theta burst TMS (cTBS) will be delivered to a location on the head, determined by randomized group assignment. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theta burst transcranial magnetic stimulation
Description: Real or sham continuous theta burst TMS (cTBS) will be delivered to a location on the head, determined by randomized group assignment. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theta burst transcranial magnetic stimulation
Description: Real or sham continuous theta burst TMS (cTBS) will be delivered to a location on the head, determined by randomized group assignment. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theta burst transcranial magnetic stimulation
Description: Real or sham continuous theta burst TMS (cTBS) will be delivered to a location on the head, determined by randomized group assignment. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theta burst transcranial magnetic stimulation
Description: Real or sham continuous theta burst TMS (cTBS) will be delivered to a location on the head, determined by randomized group assignment. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Theta burst transcranial magnetic stimulation
Description: Real or sham continuous theta burst TMS (cTBS) will be delivered to a location on the head, determined by randomized group assignment. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Theta burst transcranial magnetic stimulation
Description: Real or sham continuous theta burst TMS (cTBS) will be delivered to a location on the head, determined by randomized group assignment. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.
Study: NCT06120777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00069
Description: Noninvasive pulse oximeter
Study: NCT06596031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: The core belief in coaching is that people are resourceful and that the participant knows what is best for themselves. If the participants are assigned to the health coaching group, they will have access to a health coach with a physiotherapist background. Instead of offering physiotherapy advice, however, the health coaching will work with the participant to come up with ideas that work the best for them to manage their health and wellness to prepare for surgery, including addressing some difficulties the participant are facing when using the online resource.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital toolkit
Description: This intervention provides, via a website, self-management support of preoperative rehabilitation for hip or knee replacement based on NICE guidelines Joint replacement (primary): hip and knee. This includes guidance for patients to undertake a strengthening programme that will aid recovery, lifestyle behaviours including weight management, diet and smoking cessation, and maximising functional independence and quality of life before surgery.
Study: NCT06683482

Intervention type: OTHER
Intervention: No intervention
Description: No study drug will be administered as a part of this study.
Study: NCT06685640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prefabricated stainless steel crowns
Description: Full coverage restoration after pulpal treatment in multi-surface deep caries of primary mandibular second molars requiring pulpotomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prefabricated zirconia crowns
Description: Full coverage restoration after pulpal treatment in multi-surface deep caries of primary mandibular second molars requiring pulpotomy
Study: NCT06687681

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cell therapy
Description: Active NK cell injection through lumbar puncture in patient with Astrocytoma IDH-mutant, Oligodendroglioma IDHmutant, Glioblastoma IDH-wild type, Diffuse midline glioma, Diffuse hemispheric glioma, Diffuse pediatrictype high-grade glioma IDH-wild type
Study: NCT05726591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EA-KAFO
Description: This study tests a single device that contains multiple potential configurations as outlined in Table 1 of the protocol. Each participant be evaluated in multiple configurations, minimally including the baseline configuration and the motor assist condition at the knee.
Study: NCT06690814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ficus septica exudate (antiseptic plant exudates)
Description: F. septica sap contains the antibacterial alkaloid ficuseptine which exhibits activivity agaisnt S. pyogenes and H. ducreyi, two pàthogens associated with cutaneous ulcer disease in Papau New Guinea. The sap has been tested using the Ames test for mutagenesis, and found to be non-mutagenic; testing was carried out by toxicology service provider Gentronix, UK (results available separately on request).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pterocarpus indicus exudate
Description: P. indicus sap exhibits antibacterial activivity agaisnt S. pyogenes, a pàthogen associated with cutaneous ulcer disease in Papau New Guinea. The sap has been tested using the Ames test for mutagenesis, and found to be non-mutagenic; testing was carried out by toxicology service provider Gentronix, UK (results available separately on request).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Curcuma longa aqueous extract
Description: C. longa is a culinary herb that contains the antibatieral compound curcumin. Curcumin exhibits antibacterial activity agasint S. pyogenes and has profound effects on bacterial biofilms. This intervention uses a mulch of the rhizome that has been sqeeezed to produce a curcumin containing aqueous fluid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Savlon antiseptic cream (cetrimide with chlorhexidine digluconate)
Description: Common over the counter antiseptic cream
Study: NCT06701578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safe and Sound Protocol
Description: Listening to specially designed filtered and modulated music that is tailored to enhance the individual's auditory system's ability to process and respond to auditory stimuli for up to five hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Listening to music that is not filtered and modulated for up to five hours.
Study: NCT06701006

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated skills and safety planning app
Description: This is a digital app that includes supported safety planning resources in clinic as well as coping skills and lived experience videos for adolescents, young adults and parents/caregivers that can be accessed in clinic or at home.
Study: NCT06708533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: This intervention involves a structured 12-week walking program designed to increase routine physical activity among participants diagnosed with IBS. The intervention focuses on moderate-intensity walking, performed regularly, in line with World Health Organisation (WHO) guidelines with the aim of relieving IBS symptoms.~Key elements include:~Participants will be guided to adhere to an individualised walking protocol, ensuring consistency in activity levels.~Physical activity levels will be monitored using self-reported diaries and wearable activity trackers to ensure compliance.~Participants will also attend three scheduled visits to the university (baseline, week 6, and week 12) for biological sample collection, sub-maximal fitness assessments, and the completion of validated questionnaires on IBS symptoms, quality of life (QoL), anxiety, and depression.
Study: NCT06707012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Participants will be divided in 2 groups~1 group will receive metformin and 2nd group will receive placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin Hydrochloride
Description: Participants will be divided in 2 groups~1 group will receive metformin and 2nd group will receive placebo
Study: NCT06706765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Treatment
Description: Behavioral cough suppression therapy delivered in a group setting via telehealth.
Study: NCT06707831

Intervention type: OTHER
Intervention: Teleassessment
Description: Children underwent assessments on two occasions: one in face-to-face within a clinical setting, and the other through teleassessment using video conferencing. This video conference session was recorded to be later reviewed and scored by two separate raters.
Study: NCT06710639

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Program
Description: Instructions and recommendations will be provided in an informational leaflet to encourage an active and healthy lifestyle, promoting self-care and good health practices. This leaflet will include the new WHO guidelines recommending specific measures to reduce the risk of cognitive impairment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training Program
Description: The cognitive training program (CT) focused on everyday cognition (EC) will be conducted individually. Each participant will receive a dossier specifically designed for the study.
Study: NCT06709430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical education group
Description: Students will be divided into standardized patient and Classical education group. Theoretical courses, standardized patient-based pain management laboratory practice, and clinical practice processes will be applied to students in the experimental group.
Study: NCT06708039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Instant Messaging Application based Self-management and Exercise Programme (SMEP)for Older Adults with Chronic Knee Pain.
Description: The Mobile Instant Messaging Application based self-management and exercise programme (SMEP) consists of 10 short videos of self-management on chronic knee pain in older adults (5-10 minutes/video), 10 short videos of exercise interventions (5-10 minutes/video) and group discussions (10-20 minutes/session) with each video/session focusing on different content. A WhatsApp group that includes all participants in the intervention group will be created to deliver the three components of the program twice a week for five weeks. At the end of each session, they will be given the power point slides from the self-management video in Pdf format and an e-pamphlet of the exercise video. A total of 30-40 minutes will be allocated for each session to allow for socialization between the participants and researcher and also for a question and answer session.
Study: NCT06709313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chromium
Description: Participants in the experimental group will receive oral chromium supplementation, the dosage of which is determined based on previous studies(200 mcg daily) taking into account safety and efficacy considerations. The supplementation will commence for 45 days following the injection.
Study: NCT06709924

Intervention type: OTHER
Intervention: EXERCISE TRAINING WITHOUT MEDICATION
Description: After ingesting the capsular sensor, the participants were request to perform exercise packages and monitor the change of signal transmission rate and shift of intraabdominal pressure level.

Intervention type: OTHER
Intervention: EXERCISE TRAINING WITHOUT MEDICATION
Description: After ingesting the capsular sensor, the participants were request to perform exercise packages and monitor the change of signal transmission rate and shift of intraabdominal pressure level.
Study: NCT06710600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single oral dose of selected medicines, respectively
Description: amiodarone (Amiodaron Arcana) 200mg, diclofenac (Diclobene) 100mg, hydrochlorothiazide (HCT G.L) 25mg, pantoprazole (Pantoloc) 40mg, voriconazole (Voriconazol Aristo®) 200mg

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVA and UVB radiation
Description: The skin of the inner arm will be exposed to five fixed incremental doses of UVA and UVB. Each dose will be applied to a circular area on the inner forearm of 1 cm diameter for both UVA and UVB.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVA and UVB radiation
Description: The skin of the inner arm will be exposed to five fixed incremental doses of UVA and UVB. Each dose will be applied to a circular area on the inner forearm of 1 cm diameter for both UVA and UVB.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single oral dose of selected medicines, respectively
Description: acetylsalicylic acid (ASS Genericon) 500mg, doxycycline (Doxybene) 200mg, enalapril (Enalapril ratiopharm) 10mg, furosemide (Lasix) 40mg, verapamil (Verapabene) 80mg
Study: NCT06710652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Stimulation coil Cool-B65 A CO, located right lingual gyrus, stimulation frequency 1Hz, stimulation intensity 80% of motor threshold, number of stimuli 3 pulses/train, train interval 1s, 500 trains in total, 1500 total stimulation pulses, total stimulation time 20 min, treatment application once a day, continuous application for two weeks, 5 days a week.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Stimulation coil Cool-B65 P CO, located right lingual gyrus, stimulation frequency 1Hz, stimulation intensity 80% of motor threshold, number of stimuli 3 pulses/train, train interval 1s, 500 trains in total, 1500 total stimulation pulses, total stimulation time 20 min, treatment application once a day, continuous application for two weeks, 5 days a week.
Study: NCT06710509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: Three Messaging Nudges
Description: Patients in the Experimental Condition will receive a set of up to three email and text messages over the course of five days, while also receiving usual care which could include messaging from their practice or the electronic health record.
Study: NCT06706895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Polymeric Micelles for Injection combined with Fruquintinib Capsules
Description: Fruquintinib Capsules：4 mg / day, orally once daily on days 1-14 in 21-day cycles. If the patient has AE of grade 3 or above, the dose of fruquintinib capsules is reduced to 3 mg / day(dose discontinuation to dose reduction).~Paclitaxel Polymeric Micelles for Injection：150mg / m2 intravenously over 3 hours on Days1,8 of each 21-day cycle. Do not need special infusion device.~Paclitaxel Polymeric Micelles for Injection and Fruquintinib Capsules are used for 6 cycles. Subsequently, dual-drug or single-drug maintenance therapy was selected according to the tolerance of the patients. Subsequently, Paclitaxel Polymeric Micelles for Injection ( 120mg / m2, if the patient is intolerable, the dose can be reduced to 100mg / m2 ), until occur the disease progress, the intolerant toxicity or the patient withdrawal.
Study: NCT06707051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Group A received Trannexamic Acid 500mg three times a day for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (Doxium)
Description: Group B recieved Cap.Calcium Dobesilate 500mg 3 times a day for 5 days
Study: NCT06708377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling of masseter
Description: Experimental group included Dry needling of masseter muscle for 30 second to 2 minutes into the trigger point.~Conventional heating pad or face pad for 15 minutes. Therapeutic ultrasound with Frequency: 3MHz, Intensity: 0.75 - 1 W/cm2, Time: Based on treatment head and pulse factor. Temporomandibular joint mobilization (Maitland)-caudal glide, anterior-posterior glide, grade II, III, IV 3 reps x 3 sets per session. 6 x 6 exercise protocol of Rocabado, 6 reps per exercise x 6/day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: myofascial massage therapy on masseter muscle
Description: Control group included Myofascial massage - sliding and kneading, for 30 minutes per session/3x per week. Conventional heating pad or face pad for 15 minutes. Therapeutic ultrasound with Frequency: 3MHz, Intensity: 0.75 - 1 W/cm2, Time: Based on treatment head and pulse factor. Temporomandibular joint mobilization (Maitland)-caudal glide, anterior-posterior glide, grade II, III, IV 3 reps x 3 sets per session. 6 x 6 exercise protocol of Rocabado, 6 reps per exercise x 6/day
Study: NCT06713642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPOTFIRE ST System
Description: Polymerase chain reaction (PCR) test that identifies up to 13 different viral and bacterial pathogens in about 20 Minutes
Study: NCT06708858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: 200mg，qd，po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/ m2, IV，d1，8，q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2，IV，d1，8，q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg，IV，d1，q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg，IV，d1，q3w
Study: NCT06707402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WALK
Description: The intervention covers a personalized 24-week progressive brisk walking program. The program consists of moderate to high-intensity walking (i.e., 55-85% maximal heart rate) performed as both continuous and interval training sessions 2-3 times/week lasting 30-60 min/session. Four individually supervised sessions will be conducted in the first 2 weeks, while 1 supervised group session will be received bi-weekly. Furthermore, the group will receive an activity tracker and monthly telephone calls will be offered to adjust the intensity of the program (if necessary), clarify any questions regarding the intervention, and give verbal motivation. At the baseline assessment and at week 12, during a group training session, the figure of 8 walk test will be conducted to gain insigh tinto the current status of the training program. Lastly, after completion of the baseline test, the participants are given a brief educational session (walking advice) on recommended guidelines for physical activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACTIVE
Description: Will receive an activity tracker is provided alongside monthly telephone calls and walking advice after the baseline test. Similar to WALK, 3 telephone calls are provided during the follow-up period.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: CON
Description: Receives a brief educational session (walking advice) is provided at baseline, after which no further contacts are made.
Study: NCT06707909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menaquinone
Description: the socket will be filled with crushed capsule of vitamin k2 menaquinone in study group
Study: NCT06705062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reduced-dose PTCy
Description: Patients receiving reduced dose of PTCy at 35mg.kg on day +3 and +4 together with tacrolimus starting from day+5 and single dose of anti-thymoglobin (ATG) 2.5mg/kg at 72 hours after documentation of neutrophil engraftment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose PTCY
Description: Patients receiving standard dose PTCy at 50mg/kg on day +3 and +4 with tacrolimus starting from day +5 and single dose of anti-thymoglobin at 2.5mg/kg 72 hours after documentation of neutrophil engraftment.
Study: NCT06707090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR987 0.1% gel + Standard of Care
Description: 6mg topical gel for application plus Standard of Care (wound cleansing/dressings and compression bandaging)

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Standard of Care (wound cleansing/dressings and compression bandaging)
Study: NCT04503694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML Intravenous Solution
Description: Nivolumab will be given at a dose of 240 mg during the pre-operative phase only as indicated below:~* On day 1 and 15, during the Induction treatment~* On day 29, 43 and 57, during the Consolidation treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib 30 MG Oral Tablet
Description: Regorafenib will be administered orally once a day at a dose of 60 mg/day (2 tablets of 40 mg), during the pre-operative phase only as indicated below:~* From day 1 to 14, during the Induction treatment~* From day 29 to 49, during the Consolidation treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All study subjects will receive 5 daily fractions of radiotherapy. Each fraction will consist of 5 Gy for a total dose of 25 Gy. Radiotherapy is to start on day 22 and to finish on day 26.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Subject will undergo surgical resection of the primary tumour in the rectum between day 74 and 87. Surgery must be performed according to the principles of total mesorectal excision as described by Heald et al. The type of surgical approach (low anterior resection or abdominoperineal resection, etc.) will be left to the discretion of the treating surgeon.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-operative Management
Description: Subjects who achieve cCR after pre-operative treatment can, after discussion with the local investigator, decline surgery and opt for a non-operative management. cCR will need to be confirmed between day 67 and 74 by the following procedures per local practise:~* Digital rectal examination~* Rectal endoscopy~* Rectal MRI Subjects who achieve near cCR at the first assessment time point after pre-operative treatment, can be re-assessed 6 to 8 weeks later with the same procedures. If cCR is diagnosed, they can opt for watch \& wait, otherwise they would need to undergo surgical resection.~Subjects who opt for a non-operative management will be followed for tumour recurrence and survival for 5 years after end of treatment visit. Follow-up for these subjects will be more intensive than that for subjects undergoing surgery